Blog


On August 7th, 2019, LGM Pharma joined Kelly Smallridge, President & CEO of the Business Development Board for a round table discussion and Economic Development overview, with updates on our Business Retention & Expansion pipeline, as well as the opportunity to ask questions regarding our involvement with the BDB. About Business Development Board (BDB) The[…]

Read More

High Quality APIs For503B Outsourcing Facilities

Erlanger, Kentucky, June 24, 2019 – LGM Pharma, LLC, a leader in Active Pharmaceutical Ingredient (API) sourcing, distribution and supply chain management to the pharmaceutical and biotechnology industries, today reported that it is offering an expanded set of value-added services to support its clients who supply APIs to compounding pharmacies under section 503B of the[…]

Read More

On June 13th, 2019 LGM Pharma attended thr 3rd Annual South Florida Life Sciences Showcase. The event took place at the Miami International Airport and discussed funding life sciences projects in South Florida. Panel Session: Funding Florida Life Sciences: Where’s the Money? Shawn Titcomb, Allele Capital Partners Nancy Torres Kaufman, Beacon Capital Kathy Chiu, DeepWork[…]

Read More

United under the 2019 BIO International Convention theme, “It Starts With One,” companies, academic centers, patient groups, researchers, regulatory leaders and investors worked to progress approaches in key areas, such as drug development, patient access, gene therapy, diversity and inclusion, opioids, renewable fuels and agriculture. BIO 2019 featured over 1,800 exhibitors, more than 800 speakers,[…]

Read More

Florida International Trade and Investment Conference

Florida is one of the leading hubs in the nation for life sciences and bio-technology. Over 6,000 businesses, research centers, hospitals and other large and diverse industries call Florida home. The Florida International Trade and Investment Conference is the only statewide inbound mission program dedicated to promoting Florida as a destination for foreign direct investment[…]

Read More

On May 21, 2019 LGM Pharma attended the BioFlorida Palm Beach/Treasure Coast Event and learned about Max Planck Florida Institute for Neuroscience’s latest research initiatives from Research Group Leader Jason Christie, PhD. Max Planck Society and Scripps Research were ranked as the world’s top two stand-alone scientific institutions for biomedical research by Nature Index. The[…]

Read More

LGMPharma-Orphanion

March 18, 2019, Basel, Switzerland and Erlanger, Kentucky, USA – Orphanion AG, a CRO/CMO that focuses on contract research and manufacturing services for niche active pharmaceutical ingredients (APIs), and LGM Pharma, LLC, a leader in API sourcing, warehousing and distribution services to the pharmaceutical and biotechnology industries, today announced that they have finalized a partnering[…]

Read More

Hamilton Lenox Joins LGM Pharma as Senior VP of Business Development

ERLANGER, Kentucky / BOCA RATON, Florida — LGM Pharma, an innovation-driven active pharmaceutical ingredient (API) company, headquartered in Erlanger, Kentucky with offices in Florida, New Jersey and Israel recently announced the appointment of Hamilton J. Lenox as Senior Vice President of Business Development at the Boca Raton, Florida location. In this capacity, Mr. Lenox will[…]

Read More

Dactinomycin-graphic

Dactinomycin: CAS No: 50-76-0 No: 50-76-0 Dactinomycin (or actinomycin D) was the very first known antibiotic that helped fend off cancer. It’s now a standard chemotherapy medication being used to treat a variety of tumorous diseases. Doctors will typically reach for dactinomycin for sarcoma, ovarian cancer, and Wilm’s tumor.  It can also be used with certain types of neoplasia and skin moles. The[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service